Covered Versus Uncovered Self-expandable Metallic Stents for Malignant Gastric Outlet Obstruction
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Malignant gastric outlet obstruction can result from gastric adenocarcinoma, leading to intractable vomiting, nausea, and poor oral food intake. Although self-expandable metallic stent (SEMS) insertion has excellent technical and clinical success rates for relieving gastric outlet obstruction symptoms, the uncovered SEMS is susceptible to re-stenosis because of tumor ingrowth through openings between the stent wire filaments. Therefore, the most common reason for stent failure in uncovered stents is tumor ingrowth.
The covered SEMS has a membrane that prevents ingrowth through the mesh wall and consequently shows lower rate of re-stenosis than uncovered SEMS. However, covered SEMS has a higher risk of stent migration compared to uncovered SEMS. Recent prospective, randomized study showed that there was no significant difference between uncovered and covered SEMS in terms of stent patency rate as well as technical and clinical success rates.
Recently the investigators developed new covered SEMS for gastric outlet obstruction. This new covered SEMS has features that may contribute to reducing migration rate: 1) partially covered design; 2)less radial force in central portion of stent; 3) presence of lasso which enable position of stent to be adjusted after deployment; 4)presence of protrusion in both sides of stent. This prospective, randomized study aimed to compare the effectiveness and side effects of newly developed covered SEMS with those of uncovered SEMS in patients with malignant gastric outlet obstruction from gastric cancer.
| Condition | Intervention |
|---|---|
|
Gastric Outlet Obstruction Due to Gastric Adenocarcinoma |
Device: Covered stent (Bona stent pyloric/duodenal covered) insertion Device: Uncovered stent (Bona stent, pyloric/duodenal) insertion |
| Study Type: | Interventional |
| Official Title: | Comparison of Efficacy of Covered Versus Uncovered Self-expandable Metallic Stents for Treatment of Malignant Gastric Outlet Obstruction: a Prospective, Randomized Study |
- Stent patency at 8 weeks after stent insertion
| Study Start Date: | July 2012 |
| Arms | Assigned Interventions |
|---|---|
| Active Comparator: Covered stent (Bona stent, pyloric/duodenal covered) | Device: Covered stent (Bona stent pyloric/duodenal covered) insertion |
| Active Comparator: Uncovered stent (Bona stent, pyloric/duodenal) | Device: Uncovered stent (Bona stent, pyloric/duodenal) insertion |
Eligibility| Ages Eligible for Study: | 20 Years to 80 Years |
| Genders Eligible for Study: | Both |
Inclusion Criteria:
- age: 20-80
- patients with gastric outlet obstruction due to gastric adenocarinoma
- patients with inoperable gastric adenocarcinoma due to distant metastasis or severe comorbidity
- Gastric outlet obstruction score: 0-2
- Symptoms consistent with gastric outlet obstruction such as nausea or vomiting
- Findings consistent with gastric outlet obstruction in upper endoscopy or abdominal computed tomography
Exclusion Criteria:
- Previous history of stent insertion or endoscopic dilation for gastric outlet obstruction
- previous history of bypass surgery for gastric outlet obstruction
- Multiple level of bowel obstruction confirmed in radiographic studies such as small bowel series or abdominal computed tomography
- Borrmann type IV advanced gastric cancer
Contacts and Locations| Contact: Byung-Hoon Min | 82-2-3410-3409 | jason1080.min@samsung.com |
| Korea, Republic of | |
| Samsung Medical Center | Recruiting |
| Seoul, Korea, Republic of | |
| Contact: Byung-Hoon Min 82-2-3410-3409 jason1080.min@samsung.com | |
More Information
No publications provided
| Responsible Party: | Samsung Medical Center |
| ClinicalTrials.gov Identifier: | NCT01646476 History of Changes |
| Other Study ID Numbers: | 2012-01-075 |
| Study First Received: | July 9, 2012 |
| Last Updated: | August 5, 2012 |
| Health Authority: | South Korea: Institutional Review Board |
Additional relevant MeSH terms:
|
Adenocarcinoma Adenocarcinoma, Mucinous Gastric Outlet Obstruction Pyloric Stenosis Stomach Neoplasms Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type |
Neoplasms Neoplasms, Cystic, Mucinous, and Serous Stomach Diseases Gastrointestinal Diseases Digestive System Diseases Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site |
ClinicalTrials.gov processed this record on May 21, 2013